DOCSLIB.ORG

The Recent History of Tumour Necrosis Factor (Tnf)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Recent History of Tumour Necrosis Factor (Tnf) THE RECENT HISTORY OF TUMOUR NECROSIS FACTOR (TNF) The transcript of a Witness Seminar held by the History of Modern Biomedicine Research Group, Queen Mary University of London, on 14 July 2015 Edited by A Zarros, E M Jones, and E M Tansey Volume 60 2016 ©The Trustee of the Wellcome Trust, London, 2016 First published by Queen Mary University of London, 2016 The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 1 91019 5208 All volumes are freely available online at www.histmodbiomed.org Please cite as: Zarros A, Jones E M, Tansey E M. (eds) (2016) The Recent History of Tumour Necrosis Factor (TNF). Wellcome Witnesses to Contemporary Medicine, vol. 60. London: Queen Mary University of London. CONTENTS What is a Witness Seminar? v Acknowledgements E M Tansey and A Zarros vii Illustrations and credits ix Abbreviations xi Introduction Professor Jon Cohen xv Transcript Edited by A Zarros, E M Jones, and E M Tansey 1 Appendix 1 Timeline of important events in the history of TNF 73 Appendix 2 Simplified overview of the main biological actions of TNF in rheumatoid arthritis 75 Appendix 3 Overview of TNF inhibitors mentioned in the current Witness Seminar transcript 77 Glossary 79 Biographical notes 83 References 93 Index 105 Witness Seminars: Meetings and publications 111 WHAT IS A WITNESS SEMINAR? The Witness Seminar is a specialized form of oral history, where several individuals associated with a particular set of circumstances or events are invited to meet together to discuss, debate, and agree or disagree about their memories. The meeting is recorded, transcribed, and edited for publication. This format was first devised and used by the Wellcome Trust’s History of Twentieth Century Medicine Group in 1993 to address issues associated with the discovery of monoclonal antibodies. We developed this approach after holding a conventional seminar, given by a medical historian, on the discovery of interferon. Many members of the invited audience were scientists or others involved in that work, and the detailed and revealing discussion session afterwards alerted us to the importance of recording ‘communal’ eyewitness testimonies. We learned that the Institute for Contemporary British History held meetings to examine modern political, diplomatic, and economic history, which they called Witness Seminars, and this seemed a suitable title for us to use also. The unexpected success of our first Witness Seminar, as assessed by the willingness of the participants to attend, speak frankly, agree and disagree, and also by many requests for its transcript, encouraged us to develop the Witness Seminar model into a full programme, and since then more than 60 meetings have been held and published on a wide array of biomedical topics.1 These seminars have proved an ideal way to bring together clinicians, scientists, and others interested in contemporary medical history to share their memories. We are not seeking a consensus, but are providing the opportunity to hear an array of voices, many little known, of individuals who were ‘there at the time’ and thus able to question, ratify, or disagree with others’ accounts – a form of open peer-review. The material records of the meeting also create archival sources for present and future use. The History of Twentieth Century Medicine Group became a part of the Wellcome Trust’s Centre for the History of Medicine at UCL in October 2000 and remained so until September 2010. It has been part of the School of History, Queen Mary University of London, since October 2010, as the History of Modern Biomedicine Research Group, which the Wellcome Trust 1 See pages 111–117 for a full list of Witness Seminars held, details of the published volumes, and other related publications. v funds principally under a Strategic Award entitled ‘The Makers of Modern Biomedicine’. The Witness Seminar format continues to be a major part of that programme, although now the subjects are largely focused on areas of strategic importance to the Wellcome Trust, including the neurosciences, clinical genetics, and medical technology.2 Once an appropriate topic has been agreed, usually after discussion with a specialist adviser, suitable participants are identified and invited. As the organization of the seminar progresses and the participants list is compiled, a flexible outline plan for the meeting is devised, with assistance from the meeting’s designated chairman/moderator. Each participant is sent an attendance list and a copy of this programme before the meeting. Seminars last for about four hours; occasionally full-day meetings have been held. After each meeting the raw transcript is sent to every participant, each of whom is asked to check his or her own contribution and to provide brief biographical details for an appendix. The editors incorporate participants’ minor corrections and turn the transcript into readable text, with footnotes, appendices, a glossary, and a bibliography. Extensive research and liaison with the participants is conducted to produce the final script, which is then sent to every contributor for approval and to assign copyright to the Wellcome Trust. Copies of the original, and edited, transcripts and additional correspondence generated by the editorial process are all deposited with the records of each meeting in the Wellcome Library, London (archival reference GC/253) and will be available for study. For all our volumes, we hope that, even if the precise details of the more technical sections are not clear to the non-specialist, the sense and significance of the events will be understandable to all readers. Our aim is that the volumes inform those with a general interest in the history of modern medicine and medical science; provide historians with new insights, fresh material for study, and further themes for research; and emphasize to the participants that their own working lives are of proper and necessary concern to historians. 2 See our Group’s website at www.histmodbiomed.org. vi ACKNOWLEDGEMENTS We are very grateful to Professor Jon Cohen, Professor Sir Mark Walport, and Professor Fran Balkwill for independently suggesting the topic for this seminar, and also for advising us on suitable participants and the intended programme for discussion. Many thanks also to Professor Fran Balkwill for chairing the meeting so successfully. As with all our meetings, we depend a great deal on Wellcome Trust staff to ensure their smooth running: the Audiovisual Department, Catering, Reception, Security, and Wellcome Images. We are also grateful to Mr Akio Morishima for the design and production of this volume; the indexer Ms Cath Topliff; Mrs Sarah Beanland and Ms Fiona Plowman for proofreading; Mrs Debra Gee for transcribing the seminar; Ms Caroline Overy for assisting with running the seminar and Mr Adam Wilkinson who assisted in the organization and managing of the meeting. Finally, we thank the Wellcome Trust for supporting the Witness Seminar programme. Tilli Tansey Apostolos Zarros School of History, Queen Mary University of London vii ILLUSTRATIONS AND CREDITS* Figure A Professor Jon Cohen; provided with permission xvi Figure 1 Professor Fran Balkwill 3 Figure 2 Professor Tilli Tansey 3 Figure 3 Professor Sir Ravinder Nath (Tiny) Maini 7 Figure 4 Professor Joachim Kalden 10 Figure 5 Professor Sir Marc Feldmann 13 Figure 6 Associate Professor Richard Williams 16 Figure 7 Professor Jeremy Saklatvala 18 Figure 8 Professor Yuti Chernajovsky 28 Figure 9 Dr James (Jim) Woody; provided with permission 31 Figure 10 Professor Henning Walczak 33 Figure 11 Professor Sir Ravinder Nath (Tiny) Maini and Professor Henning Walczak 42 Figure 12 Associate Professor Richard Williams and Professor Sir Marc Feldmann 49 Figure 13 Dr Marcos Vidal and Professor Joachim Kalden 61 Table 1 Witness Seminar outline programme 5 Appendix 1 Timeline of important events in the history of TNF; illustration devised by Dr Apostolos Zarros based on data from Balkwill (2009) and Dayer (2002) 73 * Unless otherwise stated, all photographs were taken by Mr Wilde Fry, Wellcome Trust, and reproduced courtesy of the Wellcome Library, London. ix Appendix 2 Simplified overview of the main biological actions of TNF in rheumatoid arthritis; illustration devised by Dr Apostolos Zarros based on data from Feldmann (2009) and Dayer (2002) 75 Appendix 3 Overview of TNF inhibitors mentioned in the current Witness Seminar transcript; table devised by Dr Apostolos Zarros based on data from Shealy and Visvanathan (2008) and Kalliolias and Ivashkiv (2016) 77 x ABBREVIATIONS ASS argininosuccinate synthase BCG British Cytokine Group CAR chimeric antigen receptor CAT Cambridge Antibody Technology CD4 cluster of differentiation 4 CD95 cluster of differentiation 95 cDNA complementary DNA CTLA4 cytotoxic T lymphocyte-associated protein 4 DKFZ Deutsches Krebsforschungszentrum (German Cancer Research Center) DMBA 7,12-dimethylbenz[a]-anthracene EMA European Medicines Agency ERC European Research Council EULAR European League Against Rheumatism Fc fragment crystallizable FDA Food and Drug Administration (USA) GM-CSF granulocyte-macrophage colony-stimulating factor GSK GlaxoSmithKline HLA-DR human leukocyte antigen – antigen D-related ICRF Imperial Cancer Research Fund (UK) IFN interferon IFN-β IFN beta IFN-γ IFN gamma IgG immunoglobulin G IgM immunoglobulin M xi IL-1 interleukin-1 IL-1α IL-1 alpha IL-1β IL-1 beta IL1B human gene for IL-1β IL-2 interleukin-2 IL-6 interleukin-6 IL-8 interleukin-8
Load more

Recommended publications
  • Heart Failure and Drug-Induced Lupus
    Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus J.J. Cush John J. Cush, MD, Chief, Rheumatology ABSTRACT demyelinating disease, cytopenias, auto- and Clinical Immunology, Presbyterian Serious and unexpected adverse events, immune disorders, and heart failure. Hospital of Dallas, Clinical Professor of such as heart failure and drug-induced Other essays in this volume address the Internal Medicine, The University of Texas lupus, have been reported in patients subject of infection (10), demyelination Southwestern Medical School, Dallas, Texas, USA. receiving TNF inhibitor therapy. These (11), and lymphoma (12). This review events generally are easily recogniz- will focus on heart failure and lupus- Please address correspondence to: John J. Cush, MD, Presbyterian Hospital able, although they cannot be predicted like disease, which are rarely seen in of Dallas, 8200 Walnut Hill Lane, Dallas, nor avoided, other than by drug avoid- association with TNF inhibitor therapy Texax 75231-4496, USA. ance altogether. Many patients have and are currently without explanation. Clin Exp Rheumatol 2004; 22 (Suppl. 35): great benefit from anti-TNF therapies. S141-S147. Their intelligent use requires a firm Sources of data © Copyright CLINICAL AND EXPERIMENTAL understanding of these rare toxicities, As a consequence of drug approval, RHEUMATOLOGY 2004. so as to minimize the morbidity associ- manufacturers have a responsibility to ated with their uncommon occurrence. collect safety data actively and report Key words: TNF inhibitors, conges- these data to the appropriate agencies. tive heart failure, drug-induced lupus, Introduction For example, in the USA a manufactur- rheumatoid arthritis. The introduction of biologic agents to er must submit periodic safety reports specifically inhibit the pro-inflammato- to the FDA twice yearly (March and ry cytokine, tumor necrosis factor (TNF), September).
    [Show full text]
  • Cytokines MONTRÉAL 2008
    Cytokines MONTRÉAL 2008 Translating Science into Health: Cytokines in Cancer, Infl ammation and Infectious Diseases 7th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research Photo: Tourisme Montréal Photo: Tourisme October 12-16, 2008 Fairmont Queen Elizabeth Hotel Montreal Quebec CANADA Cytokines Montreal 2008 1 PROGRAM From cell separation to molecular analysis The Gold Standard in Cell Isolation • Separation of functional, cytokine-secreting cells • Virtually any cell type from any species • Superior viability, purity and recovery Cytokines and Growth Factors • New, broad portfolio: human - mouse - rat • Excellent purity and activity • Optimized for cell culture applications MACSmolecular Tools for Molecular Analysis • Tools for signal transduction • State of the art microRNA analysis • Comprehensive gene expression profiling Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. Miltenyi Biotec Inc. Phone 800 FOR MACS www.miltenyibiotec.com 12740 Earhart Avenue +1 530 888 8871 [email protected] Auburn CA 95602, USA Fax +1 530 888 8925 2 Cytokines Montreal 2008 ContentsWelcome to Montreal ..................................................................................... 4-5 Sponsors and Exhibitors ................................................................................... 6 Conference Venue ...........................................................................................
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH PrXELJANZ® tofacitinib, tablets, oral 5 mg tofacitinib (as tofacitinib citrate) 10 mg tofacitinib (as tofacitinib citrate) PrXELJANZ® XR tofacitinib extended-release, tablets, oral 11 mg tofacitinib (as tofacitinib citrate) ATC Code: L04AA29 Selective Immunosuppressant Pfizer Canada ULC Date of Preparation: 17,300 Trans-Canada Highway October 24, 2019 Kirkland, Quebec H9J 2M5 TMPF PRISM C.V. c/o Pfizer Manufacturing Holdings LLC Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2019 Submission Control No: 230976 XELJANZ/XELJANZ XR Page 1 of 80 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 ADVERSE REACTIONS..................................................................................................15 DRUG INTERACTIONS ..................................................................................................29 DOSAGE AND ADMINISTRATION..............................................................................34 OVERDOSAGE ................................................................................................................38 ACTION AND CLINICAL PHARMACOLOGY ............................................................38
    [Show full text]
  • Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal
    Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site.
    [Show full text]
  • The Role of Polyadenylation in the Induction of Inflammatory Genes
    The role of polyadenylation in the induction of inflammatory genes Raj Gandhi BSc & ARCS Thesis submitted for the degree of Doctor of Philosophy September 2016 Declaration Except where acknowledged in the text, I declare that this thesis is my own work and is based on research that was undertaken by me in the School of Pharmacy, Faculty of Science, The University of Nottingham. i Acknowledgements First and foremost, I give thanks to my primary supervisor Dr. Cornelia de Moor. She supported me at every step, always made time for me whenever I needed it, and was sympathetic during times of difficulty. I feel very, very fortunate to have been her student. I would also like to thank Dr. Catherine Jopling for her advice and Dr. Graeme Thorn for being so patient and giving me so much help in understanding the bioinformatics parts of my project. I am grateful to Dr. Anna Piccinini and Dr. Sadaf Ashraf for filling in huge gaps in my knowledge about inflammation and osteoarthritis, and to Dr. Sunir Malla for help with the TAIL-seq work. I thank Dr. Richa Singhania and Kathryn Williams for proofreading. Dr. Hannah Parker was my “big sister” in the lab from my first day, and I am very grateful for all her help and for her friendship. My project was made all the more enjoyable/bearable by the members of the Gene Regulation and RNA Biology group, especially Jialiang Lin, Kathryn Williams, Dr. Richa Singhania, Aimée Parsons, Dan Smalley, and Hibah Al-Masmoum. Barbara Rampersad was a wonderful technician. Mike Thomas, James Williamson, Will Hawley, Tom Upton, and Jamie Ware were some of the best of friends I could have hoped to make in Nottingham.
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • PATIENT FACT SHEET TNF Inhibitors
    PATIENT FACT SHEET TNF Inhibitors TNF inhibitors are used worldwide to treat symptoms. TNF inhibitors can control inflammation in inflammatory conditions such as rheumatoid arthritis the joints, gastrointestinal tract and skin. There are six (RA), psoriatic arthritis, juvenile arthritis, inflammatory different TNF inhibitors that have been approved by bowel disease (Crohn’s and ulcerative colitis), ankylosing the FDA for the treatment of rheumatic diseases. To spondylitis and psoriasis. They reduce inflammation decrease side effects and costs, most patients with and can stop disease progression by targeting an mild or moderate disease are treated with methotrexate inflammation causing substance called Tumor Necrosis before adding or switching to a TNF inhibitor. These WHAT IS IT? Factor (TNF). In healthy individuals, excess TNF in agents can be used by themselves or in combination the blood is blocked naturally, but in those who have with other medications such as prednisone, rheumatic conditions, higher levels of TNF in the methotrexate, hydroxychloroquine, leflunomide blood can lead to more inflammation and persistent or sulfasalazine. TNF inhibitors may be given by injection under the the same site is not used multiple times. Infliximab and skin or by infusion into the vein. There are pamphlets golimumab infusions are administered at a doctor’s and videos that can teach you how to give yourself office or an infusion center. These treatments take up an injection under the skin. Physicians, nurses, and to 4 hours. The time that it takes for the medication to pharmacists can also teach you how to give the injection. have an effect may vary by patient.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Initial Safety Trial Results Find Increased Risk of Serious Heart-Related
    Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) FDA will evaluate the trial results FDA previously communicated about the safety clinical trial with Xeljanz, Xeljanz XR (tofacitinib) in February 2019 and July 2019. 2-4-2021 FDA Drug Safety Communication The U.S. Food and Drug Administration (FDA) is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death. Those final results are not yet available. We will evaluate the clinical trial results we have received to date and will work with the drug manufacturer to obtain further information as soon as possible. We will communicate our final conclusions and recommendations when we have completed our review or have more information to share. Patients should not stop taking tofacitinib without first consulting with your health care professionals, as doing so may worsen your condition. Talk to your health care professionals if you have any questions or concerns. Health care professionals should consider the benefits and risks of tofacitinib when deciding whether to prescribe or continue patients on the medicine. Continue to follow the recommendations in the tofacitinib prescribing information. Tofacitinib was first approved in 2012 to treat adults with rheumatoid arthritis (RA) who did not respond well to the medicine methotrexate.
    [Show full text]
  • 2008-05-13-Professors Marc Feldmann and Sir Ravinder Maini
    Contact: Seema Kumar Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (908) 218-6460 or [email protected] Frederik Wittock Johnson & Johnson Pharmaceutical Research & Development (Belgium) +32 14 60 57 24 or [email protected] Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research New York, N.Y. – May 13, 2008 – Johnson & Johnson today announced that Professor Marc Feldmann, FMedSci, FAA, FRS and Emeritus Professor Sir Ravinder N. Maini, FRCP, FMedSci, FRS of the Kennedy Institute of Rheumatology, Imperial College London have been named the recipients of the 2008 Dr. Paul Janssen Award for Biomedical Research by an independent selection committee of world-renowned scientists. The award salutes the most passionate and creative scientists in basic or clinical research, whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. Feldmann and Maini were selected for their role in the discovery of tumor necrosis factor-alpha, or TNF-alpha, as an effective therapeutic target for rheumatoid arthritis and other chronic inflammatory conditions afflicting millions worldwide. The award, which includes a $100,000 prize, will be presented to the winners at events in New York and Beerse, Belgium in September. According to Solomon Snyder, Ph.D., Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine and Chairman, Janssen Award Selection Committee, “The work of Feldmann and Maini exemplifies the bench-to-bedside approach that Paul Janssen’s contributions epitomized. It is extremely rare for researchers to identify a molecular messenger in test tube studies, demonstrate its physiologic relevance in animals and themselves carry these efforts forward to a successful clinical demonstration.
    [Show full text]